Literature DB >> 6247106

The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour.

J G Klijn, S W Lamberts, F H de Jong, R Docter, K J Van Dongen, J C Birkenhäger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6247106     DOI： 10.1111/j.1365-2265.1980.tb02719.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  7 in total

1.  Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.

Authors:  M Losa; R L Barzaghi; P Mortini; A Franzin; F Mangili; M R Terreni; M Giovanelli
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.

Authors:  J G Klijn
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

3.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

4.  A practical approach to the investigation of the hyperprolactinaemic patient.

Authors:  S M Shalet; A J Chapman; E Whitehead; C G Beardwell
Journal:  Postgrad Med J       Date:  1981-08       Impact factor: 2.401

5.  Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.

Authors:  Tomohiro Kawaguchi; Yoshikazu Ogawa; Teiji Tominaga
Journal:  BMC Res Notes       Date:  2014-08-20

6.  Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline.

Authors:  Wael M Almistehi; Mussa H Almalki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-08-23

7.  Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

Authors:  J G Klijn; A M Hoff; A S Planting; J Verweij; T Kok; S W Lamberts; H Portengen; J A Foekens
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.